An observational study in Aortic Stenosis, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by University of Edinburgh · Observational
Among 107 studies in Aortic Valve Stenosis with a site in United Kingdom — 20 open to participants now, 34 under way, 2 of them phase 3. Aortic Valve Stenosis · United Kingdom.
Among the 107 studies in Aortic Valve Stenosis with a site in United Kingdom, this one is the 27th largest by planned enrollment of the 61 observational ones that give a count, is one of 5 that started in 2023, is one of 61 observational ones, reaches primary completion later than 29 of the 33 other live ones, and was the 95th registered.
1,025 studies on the registry are indexed under Aortic Valve Stenosis; 293 are open to participants now.
This study's planned enrollment of 300 is above the median of 200 across 435 observational studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →20 of the 107 studies in Aortic Valve Stenosis with a site in United Kingdom are open now.
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 5
First in 2006; this study’s year is marked. 5 started in 2023.
Median enrollment 215 across the 46 interventional studies, 252 across the 61 observational. Of the 66 that completed or were terminated, 22 (33%) have results posted.
57 of 107 have an industry lead sponsor. The 10 most frequent:
University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.
University of Edinburgh has 9 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Aortic Valve Stenosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596460Barts & The London NHS TrustA Study to Obtain Imaging Data in 40 Patients Having Transcatheter Aortic Valve Implantation (TAVI) | 2026-12-12 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
| NCT06602609Imperial College LondonRemote Cardiovascular Monitoring in Post-TAVI Patients | 2027-07-01 |
| NCT06507579Sahajanand Medical Technologies LimitedHydra Registry - UK | 2027-07-11 |
Among the 107 studies in Aortic Valve Stenosis with a site in United Kingdom, from their registry updates:
The goal of this observational study is to understand the processes of what causes and accelerates the disease progress in aortic stenosis and following aortic valve replacement.
Participants will undergo transthoracic echocardiography every 6 months, with annual visits for state-of-the-art scanning techniques including positron-emission tomography combined with computed tomography or magnetic resonance imaging with radiotracers designed to look at disease processes including fibrosis, calcification, inflammation and thrombosis activity.
This will be an observational cohort study using existing and prospectively recruited cohorts for both cross-sectional and longitudinal comparison across the spectrum of aortic stenosis severity. For existing cohorts of patients who have previously undergone research assessments, we will invite them for repeated assessments.
Participants will be reviewed every 6 months in the Clinical Research Facility (CRF) over a 4-year period. They will undergo clinical assessment, blood sampling, transthoracic echocardiography and advanced imaging annually including CT angiography, magnetic resonance and positron emission tomography (PET).
We will recruit up to 300 patients with aortic valve disease across the spectrum of disease severities from aortic sclerosis through to mild, moderate and severe aortic stenosis as defined by the European Society of Cardiology. We will also include those who have undergone bioprosthetic aortic valve replacement, and age and sex-matched control subjects with normal aortic valves.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Aortic Stenosis across the spectrum of disease severity
Radiation: PET-CT
Participants who have previously undergone aortic valve replacement
Radiation: PET-CT
Healthy Volunteers for the purposes of case-control analysis
Radiation: PET-CT
PET combined with CT or MRI
Also known as: Positron Emission Tomography
Haemodynamic aortic valve disease progression.
Rate of change of maximal aortic valve jet velocity (AV Vmax)
Time frame: 4 years
Inflammatory, thrombotic, fibrotic and calcific aortic valve disease progression.
Rate of change of tissue-to-background ratio (TBRmax) of FDG, GP1, FAPI and NaF PET.
Time frame: 4 years
Plan to share: Yes
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: End of Study to 15 years
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for May 2028, 60 months after the start.
Of 205 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 60 months is above that.
Counting every sponsor, half of 242 studies reached it within 42 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.